Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Thera
Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh